Cargando…

Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency

Background and aim: The value of the forced expiratory volume in one second (FEV(1)) is useful in the diagnosis and prognosis of chronic obstructive pulmonary disease (COPD). Previous studies on lung function in individuals with severe alpha-1 antitrypsin deficiency (AATD) have shown a variable annu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hiller, Adriana-Maria, Piitulainen, Eeva, Jehpsson, Lars, Tanash, Hanan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536893/ https://www.ncbi.nlm.nih.gov/pubmed/31213789 http://dx.doi.org/10.2147/COPD.S195847

Ejemplares similares

The Clinical Course of Severe Alpha-1-Antitrypsin Deficiency in Patients Identified by Screening
por: Hiller, Adriana-Maria, et al.
Publicado: (2022)

Liver disease in adults with severe alpha-1-antitrypsin deficiency
por: Tanash, Hanan A., et al.
Publicado: (2019)

Liver function in alpha-1-antitrypsin deficient individuals at 37 to 40 years of age
por: Mostafavi, Behrouz, et al.
Publicado: (2017)

Cause-specific mortality in individuals with severe alpha 1-antitrypsin deficiency in comparison with the general population in Sweden
por: Tanash, Hanan A, et al.
Publicado: (2016)

Survival in severe alpha-1-antitrypsin deficiency (PiZZ)
por: Tanash, Hanan A, et al.
Publicado: (2010)

Lung Function and Health Status in Individuals with Severe Alpha-1-Antitrypsin Deficiency at the Age of 42
por: Schramm, Georg Rüdiger, et al.
Publicado: (2021)

Survival in the Swedish cohort with alpha-1-antitrypsin deficiency, up to the age of 43–45 years
por: Mostafavi, Behrouz, et al.
Publicado: (2019)

Acoustic radiation force impulse (ARFI) elastography in a cohort of alpha-1 antitrypsin-deficient individuals and healthy volunteers
por: Diaz, Sandra, et al.
Publicado: (2018)

Decreased Risk of Ischemic Heart Disease in Individuals with Severe Alpha 1-Antitrypsin Deficiency (PiZZ) in Comparison with the General Population
por: Tanash, Hanan, et al.
Publicado: (2020)

Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37–40 years
por: Piitulainen, Eeva, et al.
Publicado: (2017)

Lung function and CT lung densitometry in 37- to 39-year-old individuals with alpha-1-antitrypsin deficiency
por: Mostafavi, Behrouz, et al.
Publicado: (2018)

Lung transplantation and survival outcomes in patients with oxygen-dependent COPD with regard to their alpha-1 antitrypsin deficiency status
por: Ekström, Magnus, et al.
Publicado: (2017)

Low Prevalence of Mild Alpha-1-Antitrypsin Deficiency in Hospitalized COVID-19-Patients
por: Nygren, David, et al.
Publicado: (2022)

Endotoxin receptor CD14 in PiZ α-1-antitrypsin deficiency individuals
por: Sandström, Caroline S, et al.
Publicado: (2008)

Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry
por: Rahaghi, Franck F, et al.
Publicado: (2020)

Long-term effect of α(1)-antitrypsin augmentation therapy on the decline of FEV(1) in deficient patients: an analysis of the AIR database
por: Schouten, Iris G.M., et al.
Publicado: (2021)

Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry
por: Miravitlles, Marc, et al.
Publicado: (2022)

Plasma levels of alpha1-antichymotrypsin and secretory leukocyte proteinase inhibitor in healthy and chronic obstructive pulmonary disease (COPD) subjects with and without severe α1-antitrypsin deficiency
por: Hollander, Camilla, et al.
Publicado: (2007)

Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency
por: Parr, David G, et al.
Publicado: (2009)

Correction: Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry
por: Miravitlles, Marc, et al.
Publicado: (2023)

Impact of COVID-19 in Patients With Severe Alpha-1 Antitrypsin Deficiency: The IMCA1 Study of the EARCO Clinical Research Collaboration
por: Parr, David G., et al.
Publicado: (2022)

Mineralization of alpha-1-antitrypsin inclusion bodies in Mmalton alpha-1-antitrypsin deficiency
por: Callea, Francesco, et al.
Publicado: (2018)

Gene therapy for alpha 1-antitrypsin deficiency with an oxidant-resistant human alpha 1-antitrypsin
por: Sosulski, Meredith L., et al.
Publicado: (2020)

Alpha-1 Antitrypsin as a Therapeutic Agent for Conditions not Associated with Alpha-1 Antitrypsin Deficiency
por: Wanner, Adam
Publicado: (2015)

Severe bilateral descemetoceles in Alpha-1 antitrypsin deficiency
por: Ma, Jeffrey, et al.
Publicado: (2019)

Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis
por: Bouzek, Drake C., et al.
Publicado: (2022)

The prevalence of liver abnormalities in individuals with ZZ Alpha-1 Antitrypsin deficiency
por: McElvaney, OF, et al.
Publicado: (2015)

Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency – analysis from the German Registry
por: Bernhard, Nikolas, et al.
Publicado: (2017)

Augmentation therapy with human alpha-1-proteinase inhibitor reduces exacerbations in patient with bronchiectasis and alpha-1-antitrypsin deficiency
por: Buck, Emanuel, et al.
Publicado: (2022)

Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency
por: Petrache, Irina, et al.
Publicado: (2009)

alpha1-Antitrypsin deficiency and hepatocellular cancer.
por: Kew, M. C., et al.
Publicado: (1978)

The prevalence of alpha-1 antitrypsin deficiency in Ireland
por: Carroll, Tomás P, et al.
Publicado: (2011)

Alpha-1 Antitrypsin Deficiency: The Learning Goes On
por: Stockley, Robert. A.
Publicado: (2020)

Monocytes and Macrophages in Alpha-1 Antitrypsin Deficiency
por: Belchamber, Kylie B R, et al.
Publicado: (2020)

Alpha-1 Antitrypsin Deficiency: Home Therapy
por: Annunziata, Anna, et al.
Publicado: (2021)

Routine spirometry in cystic fibrosis patients: impact on pulmonary exacerbation diagnosis and FEV(1) decline
por: de Aquino, Carolina Silva Barboza, et al.
Publicado: (2022)

Acute Disseminated Panniculitis Associated with Alpha-1 Antitrypsin Deficiency
por: Murinello, António Guilherme, et al.
Publicado: (2022)

Lung Inflammation in alpha-1-antitrypsin deficient individuals with normal lung function
por: Kokturk, Nurdan, et al.
Publicado: (2023)

Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications
por: Chapman, Kenneth R, et al.
Publicado: (2018)

Structural characterization and conformational dynamics of alpha-1 antitrypsin pathogenic variants causing alpha-1-antitrypsin deficiency
por: Shaik, Noor Ahmad, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h14qd399tm0up2hql004i06ut0